CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma
Condition(s):B-cell Acute Lymphoblastic Leukemia; B-Cell Lymphoma, UnspecifiedLast Updated:March 18, 2024Withdrawn
Hide Studies Not Open or Pending
Condition(s):B-cell Acute Lymphoblastic Leukemia; B-Cell Lymphoma, UnspecifiedLast Updated:March 18, 2024Withdrawn
Condition(s):Diffuse Large B-Cell LymphomaLast Updated:April 28, 2023Completed
Condition(s):Relapsed Non Hodgkin LymphomaLast Updated:May 30, 2018Unknown status
Condition(s):Lymphoma; Lymphoma, B-Cell; Immune System Diseases; Immunoproliferative Disorders; Lymphatic DiseasesLast Updated:June 18, 2023Recruiting
Condition(s):Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia; Non-Hodgkin’s Lymphoma Refractory; Non-Hodgkin’s Lymphoma, RelapsedLast Updated:January 5, 2024Recruiting
Condition(s):CD19+ Malignancies: Relapse Post-allogeneic TransplantLast Updated:June 22, 2023Completed
Condition(s):Acute Lymphoblastic Leukemia; Immune System Diseases; Immunoproliferative DisordersLast Updated:January 31, 2024Recruiting
Condition(s):B Acute Lymphoblastic LeukemiaLast Updated:March 7, 2024Completed
Condition(s):Acute Lymphoblastic Leukemia; Immune System Diseases; Immunoproliferative DisordersLast Updated:December 3, 2021No longer available
Condition(s):Acute Lymphoblastic Leukemia; Large B-cell LymphomaLast Updated:March 18, 2024Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.